We previously found that ferroportin-1 (FPN) protein expression that exports iron out of cells is reduced upon treatment with siramesine and lapatinib in breast cancer cells and overexpression of FPN blocks cell death [1]. Here, SLC40A1 is linked to breast carcinoma.